Lineage Cell Therapeutics, Inc.
Sağlık
NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.
$0.99
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
WebsiteAnalysis (Turkish): LCTX Hissesi Caiz mi, Helal mi? Lineage Cell Therapeutics, Inc. Katılım Analizi